专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP4321157A3 NEW USE OF A COMBINATION OF AN ANGIOTENSIN RECEPTOR BLOCKER (ARB) WITH A NEUTRAL ENDOPEPTIDASE INHIBITOR (NEPI) 有权
公开(公告)号：EP4321157A3
公开(公告)日：2024-05-15
申请号：EP23202190.7
申请日：2014-08-26
申请人： Novartis AG
发明人： SHI, Victor Chengwei , LEFKOWITZ, Martin , RIZKALA, Adel Remond
IPC分类号： A61K31/194 , A61K31/197 , A61K31/216 , A61K31/41 , A61K31/221 , A61K45/06 , A61K31/401 , A61K31/225 , A61P9/12 , A61P9/10
CPC分类号： A61K45/06 , A61K31/225 , A61K31/401 , A61K31/41 , A61P9/10 , A61P9/12
摘要： The present invention relates to methods and pharmaceutical compositions for the prevention or in delaying time to first occurrence of mortality, in particular cardiovascular death, and/or of cardiovascular hospitalizations in a patient suffering from chronic systolic heart failure, comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of an Angiotensin Receptor Neprilysin inhibitor (ARNi) or of a combination of an Angiotensin Receptor Blocker (ARB) with a Neutral Endopeptidase inhibitor (NEPi) or with a NEPi pro-drug to said patient.

2. 发明授权

EP3426182B1 METHODS AND COMPOSITIONS FOR DENTAL TISSUE REPAIR AND/OR REGENERATION 有权
公开(公告)号：EP3426182B1
公开(公告)日：2024-05-01
申请号：EP17763983.8
申请日：2017-03-08
IPC分类号： A61K35/32 , A61L27/16 , A61L27/38 , A61L27/52 , A61K6/54 , A61K31/215 , A61K31/225 , A61K31/27
CPC分类号： A61C5/00 , A61L27/16 , A61L27/52 , A61K35/32 , A61L2430/1220130101 , A61L27/3834 , A61K31/215 , A61K31/27 , A61K31/225 , A61K6/54

3. 发明公开

EP3416634A1 IMMUNOMODULATORY AGENTS AND METHODS OF USE THEREOF 无效
公开(公告)号：EP3416634A1
公开(公告)日：2018-12-26
申请号：EP17753696.8
申请日：2017-02-14
申请人： Artyomov, Maxim , Lampropoulou, Vicky
发明人： Artyomov, Maxim , Lampropoulou, Vicky
IPC分类号： A61K31/19 , A61K31/194
CPC分类号： A61K31/194 , A61K31/225
摘要： The disclosure provides a method of suppressing an immune response comprising administration of an immunomodulatory agent. The disclosure further provides for an immunomodulatory agent comprising itaconate, malonate, or a derivative thereof. Further, the disclosure provides for a method of reducing the extent of tissue injury in ischemia reperfusion, including cardiovascular infarction comprising administration of an immunomodulatory agent and treating psoriasis.

4. 发明授权

EP2991640B1 A MULTIPART FLUID SYSTEM AND A SYSTEM FOR CITRATE ANTICOAGUALATION IN AN EXTRACORPOREAL BLOOD CIRCUIT 有权
公开(公告)号：EP2991640B1
公开(公告)日：2018-12-05
申请号：EP14721347.4
申请日：2014-04-30
申请人： Gambro Lundia AB
发明人： ÅHL, Petra , GODALY, Gabriela , STERNBY, Jan , WIESLANDER, Anders
IPC分类号： A61K31/194 , A61K31/7004 , A61K33/10 , A61K33/14 , A61K33/42 , A61P7/08 , A61K9/08 , A61M1/34
CPC分类号： A61K33/42 , A61K9/0019 , A61K9/0026 , A61K31/194 , A61K31/225 , A61K31/7004 , A61K33/00 , A61K33/06 , A61K33/10 , A61K33/14 , A61K47/02 , A61M1/1654 , A61M1/1672 , A61M1/342 , A61M1/3434 , A61M1/3437 , A61M1/3441 , A61M1/3672 , A61M1/3675 , A61K2300/00
摘要： The present invention concerns a multipart fluid system for dialysis therapy, wherein the multipart fluid system comprises an anticoagulation fluid and at least one treatment fluid from the group consisting of dialysis fluid and infusion fluids. According to the invention the anticoagulation fluid comprises 15-40 mM citrate; and the at least one treatment fluid comprises 1.5-8 mM citrate and ≧10 mM bicarbonate. The present invention further concerns a system for citrate anticoagulation in an extracorporeal blood circuit.

5. 发明公开

EP3368025A1 COMBINATION COMPRISING PTEROSTILBENE FOR THE TREATMENT OF CANCER 审中-实审
公开(公告)号：EP3368025A1
公开(公告)日：2018-09-05
申请号：EP16730305.6
申请日：2016-06-09
申请人： Fundación Universidad Católica de Valencia San Vicente Mártir , Universitat De València, Estudi General , Fundació Investigació Hospital General Universitari de València per a la Investigació Biomedica I Ciencies de la Salut , IDCQ Hospitales y Sanidad, S.L.U.
发明人： ESTRELA ARIGÜEL, José María , BENLLOCH GARCÍA, María , PLÁ OBRADOR, María Elena , VALLÉS MARTÍN, Lilian Soraya , RODRÍGUEZ ROMERO, María Lucía , SIREROL TALENS, Joan Antoni , ALCÁCER GARCÍA, Javier Luis , PELLICER ARTÉS, José Alfredo , SALVADOR PALMER, Rosario , SÁEZ TORMO, Guillermo María , CERDÁ MICÓ, Concepción
IPC分类号： A61K31/09 , A61P35/00
CPC分类号： A61K31/09 , A61K31/225 , A61K31/277 , A61K31/42 , A61K31/4412 , A61K31/551 , A61K31/635 , A61P35/00 , A61K2300/00
摘要： The present invention relates to a combination comprising pterostilbeneor pterostilbene phosphate or a pharmaceutically acceptable salt thereof, a glutathione depleting agent and a cancer chemotherapeutic agent. The invention also relates to the medical use of this combination, in particular for the treatment and/or prevention of cancer.

6. 发明公开

EP3360572A1 DEVELOPMENT OF DIETARY THERAPY IN CANCER 无效
公开(公告)号：EP3360572A1
公开(公告)日：2018-08-15
申请号：EP16841134.6
申请日：2016-09-02
申请人： Osaka University , Meiji Co., Ltd.
发明人： HAGIHARA, Keisuke , ASHIDA, Kinya , TONOUCHI, Hidekazu , NAKAMURA, Kentaro
IPC分类号： A61K45/00 , A61K31/22 , A61K31/7016 , A61P35/00 , A61P43/00
CPC分类号： A61K31/225 , A23L33/115 , A23L33/30 , A23V2002/00 , A61K31/22 , A61K31/7016 , A61K45/00 , A61P35/00
摘要： The invention provides new compositions or combinations thereof for the treatment of cancer. More specifically, the invention provides compositions or combinations thereof for cancer treatment including a high-fat diet. Specifically, the high-fat diet is characterized by having approximately 120 g/day or more, or approximately 70% or more of the total daily energy, from fat, based on a real body weight of 50 kg. The diet is preferably a carbohydrate-restricted high-fat diet, and more preferably provided by a ketone formula and/or MCT oil. The dietary therapy by a high-fat diet of the present invention is provided along with surgical treatment, chemotherapy or radiation therapy, or combinations thereof.

7. 发明公开

EP3328376A1 METHODS AND COMPOSITIONS FOR TREATING METABOLIC REPROGRAMMING DISORDERS 审中-实审
公开(公告)号：EP3328376A1
公开(公告)日：2018-06-06
申请号：EP16833633.7
申请日：2016-07-29
申请人： The Johns Hopkins University
发明人： SLUSHER, Barbara , POWELL, Jonathan
IPC分类号： A61K31/198 , A61K31/66 , A61K31/357 , A61K31/421 , A61K31/404 , A61K45/06
CPC分类号： A61K31/4045 , A61K31/22 , A61K31/225 , A61K31/42 , A61K31/655 , A61K31/664 , A61K31/683 , A61K31/685 , A61K31/7034 , A61K31/7076 , A61K35/17 , A61K39/0011 , A61K39/39541 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61P35/00 , C07K16/2818 , C07K2317/76 , Y02A50/412 , A61K2300/00
摘要： and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2′, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).

8. 发明授权

EP2970101B1 PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES 有权
公开(公告)号：EP2970101B1
公开(公告)日：2018-06-06
申请号：EP14767892.4
申请日：2014-03-14
申请人： Alkermes Pharma Ireland Limited
发明人： ZEIDAN, Tarek, A. , DUNCAN, Scott , HENCKEN, Christopher, P. , WYNN, Thomas, Andrew , SANRAME, Carlos, N.
IPC分类号： C07C219/08 , C07C229/16 , C07C309/18 , C07C229/12 , A61K31/221
CPC分类号： A61K31/225 , C07C219/08 , C07C229/16 , C07C233/18 , C07C233/91 , C07C317/18 , C07C317/28 , C07D207/06 , C07D207/40 , C07D209/52 , C07D211/06 , C07D211/38 , C07D295/088 , C07D491/113
摘要： The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.

9. 发明公开

EP3318254A1 AZELAIC ACID COMPOSITION HAVING ADIPOSE TISSUE TRIGLYCERIDE DEGRADATION EFFECT 有权
标题翻译：具有脂肪组织的甘油酸组合物甘油三酯降解效果
公开(公告)号：EP3318254A1
公开(公告)日：2018-05-09
申请号：EP16821568.9
申请日：2016-06-27
申请人： Korea University Research and Business Foundation
发明人： LEE, Sung-Joon
IPC分类号： A61K31/20 , A61K31/225 , A61K31/23
CPC分类号： A61K31/20 , A61K31/225 , A61K31/23 , A61P3/04
摘要： The present invention relates to a pharmaceutical composition or a functional food containing azelaic acid as an active ingredient and, more specifically, to a pharmaceutical composition and a health functional food, which contain, as an active ingredient, azelaic acid having an effect of lowering the accumulation of triglycerides, by allowing Olfr544, which is a GPCR expressed in cell membranes of adipose tissue, to be activated through coupling with azelaic acid such that the hydrolysis of triglycerides in adipose tissue is promoted through a cAMP-PKA-HSL signaling pathway. The composition containing azelaic acid, according to the present invention, has an excellent effect in the alleviation of the accumulation of lipids in adipose tissue and of the lipid metabolism of adipose tissue, thereby being usable as a food material, a pharmaceutical composition, and a health functional food for alleviating the lipid metabolism of adipose tissue (obesity alleviation) such as in body weight reduction and body fat reduction.
摘要翻译：含有壬二酸作为有效成分的药物组合物或功能性食品本发明涉及含有壬二酸作为有效成分的药物组合物或功能性食品，更具体地说，涉及含有壬二酸作为有效成分的药物组合物和保健功能性食品，通过允许Olfr544（其在脂肪组织的细胞膜中表达的GPCR）中的Olfr544通过与壬二酸偶联来活化，从而通过cAMP-PKA-HSL信号传导途径促进脂肪组织中的甘油三酯的水解，从而积累甘油三酯。根据本发明，含有壬二酸的组合物在减轻脂肪组织中的脂质蓄积和脂肪组织的脂质代谢方面具有优异的效果，由此可用作食品材料，药物组合物和用于减轻脂肪组织的脂质代谢（减轻肥胖）的保健功能性食品，例如减轻体重和减少体脂。

10. 发明公开

EP3316879A1 DIACEREIN OR RHEIN TOPICAL FORMULATIONS AND USES THEREOF 审中-公开
标题翻译： DIACEREIN或RHEIN局部用制剂及其用途
公开(公告)号：EP3316879A1
公开(公告)日：2018-05-09
申请号：EP16818753.2
申请日：2016-06-30
申请人： TWI Biotechnology, Inc.
发明人： BROWN, III, Carl, Oscar , CHEN, Chih-Kuang , LEE, Jing-Yi , LU, Wei-Shu
IPC分类号： A61K31/192 , A61K31/235
CPC分类号： A61K9/06 , A61K9/0014 , A61K31/192 , A61K31/225 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/183 , A61K47/26 , A61K47/32 , A61K47/44
摘要： A topical pharmaceutical composition containing diacerein and/or its analogs is provided. Also provided is a method for treating various diseases using this topical pharmaceutical composition.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式